HMGB1 secretion during cervical carcinogenesis promotes the acquisition of a tolerogenic functionality by plasmacytoid dendritic cells

Acquisition of an impaired functionality by plasmacytoid dendritic cells (pDCs) contributing to cancer progression has been documented in different types of cancers. In the present study, we postulate that molecules secreted by (pre)neoplastic epithelial cells of the genital tract (cervix/vulva) might attract pDCs but also modify their proper functionality, allowing these cells to initiate a tolerogenic response interfering with antitumor immunity. We demonstrated that pDCs are recruited during the cervical metaplasia‐dysplasia‐cancer sequence, through the action of their chemoattractant, chemerin. We showed that stimulated‐pDCs exposed to cervical/vulvar tumor microenvironment display an altered phenotype. We also demonstrated that cervical/vulvar neoplastic keratinocytes inhibit the proper function of pDCs by decreasing their IFNα secretion in response to CpG oligonucleotides. In parallel, we observed that (pre)neoplastic areas of the cervix are infiltrated by FoxP3+ Treg cells which colocalize with pDCs. Accordingly, pDCs cocultured with cervical/vulvar neoplastic keratinocytes have the capacity to induce a Treg cell differentiation from naïve CD4+ T cells, which is in agreement with the development of a tolerogenic response. We identified HMGB1 as a soluble factor produced by neoplastic keratinocytes from the genital tract involved in pDCs functional alteration. Indeed, this molecule inhibited pDC maturation, decreased IFNα secretion following TLR9 stimulation and forced these cells to become tolerogenic. In contrast, inhibition of HMGB1 restored pDC phenotype. Our findings indicate that the use of inhibitory molecules notably directed against HMGB1 in cervical/vulvar (pre)neoplastic lesions might prevent alterations of pDCs functionality and represent an attractive therapeutic strategy to overcome immune tolerance in cancers.

[1]  J. Blay,et al.  Tumor promotion by intratumoral plasmacytoid dendritic cells is reversed by TLR7 ligand treatment. , 2013, Cancer research.

[2]  B. Schmidt,et al.  Identification of novel oligonucleotides from mitochondrial DNA that spontaneously induce plasmacytoid dendritic cell activation , 2013, Journal of leukocyte biology.

[3]  M. Lotze,et al.  HMGB1 in Cancer: Good, Bad, or Both? , 2013, Clinical Cancer Research.

[4]  P. Delvenne,et al.  Tumor microenvironment converts plasmacytoid dendritic cells into immunosuppressive/tolerogenic cells: insight into the molecular mechanisms , 2013, Journal of leukocyte biology.

[5]  D. Rosenberg,et al.  Multifaceted roles of PGE2 in inflammation and cancer , 2013, Seminars in Immunopathology.

[6]  J. Blay,et al.  ICOS-ligand expression on plasmacytoid dendritic cells supports breast cancer progression by promoting the accumulation of immunosuppressive CD4+ T cells. , 2012, Cancer research.

[7]  G. Siegal,et al.  Depletion of Plasmacytoid Dendritic Cells Inhibits Tumor Growth and Prevents Bone Metastasis of Breast Cancer Cells , 2012, The Journal of Immunology.

[8]  H. Zeng,et al.  In vitro-expanded CD4(+)CD25(high)Foxp3(+) regulatory T cells controls corneal allograft rejection. , 2012, Human immunology.

[9]  J. Blay,et al.  Impaired IFN-α production by plasmacytoid dendritic cells favors regulatory T-cell expansion that may contribute to breast cancer progression. , 2012, Cancer research.

[10]  A. Westendorf,et al.  HMGB1 conveys immunosuppressive characteristics on regulatory and conventional T cells. , 2012, International immunology.

[11]  J. Blay,et al.  Plasmacytoid dendritic cells infiltrating ovarian cancer are associated with poor prognosis , 2012, Oncoimmunology.

[12]  H. Møller,et al.  Intratumoral neutrophils and plasmacytoid dendritic cells indicate poor prognosis and are associated with pSTAT3 expression in AJCC stage I/II melanoma , 2012, Cancer.

[13]  S. Lang,et al.  HMGB1 is overexpressed in tumor cells and promotes activity of regulatory T cells in patients with head and neck cancer. , 2012, Oral oncology.

[14]  P. Delvenne,et al.  Production of large numbers of plasmacytoid dendritic cells with functional activities from CD34(+) hematopoietic progenitor cells: use of interleukin-3. , 2012, Experimental hematology.

[15]  J. Blay,et al.  Quantitative and functional alterations of plasmacytoid dendritic cells contribute to immune tolerance in ovarian cancer. , 2011, Cancer research.

[16]  J. Wagner,et al.  Generation and Large‐Scale Expansion of Human Inducible Regulatory T Cells That Suppress Graft‐Versus‐Host Disease , 2011, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[17]  Ziqiang Zhu,et al.  FOXO3 programs tumor-associated DCs to become tolerogenic in human and murine prostate cancer. , 2011, The Journal of clinical investigation.

[18]  P. Delvenne,et al.  Mucosal junctions: open doors to HPV and HIV infections? , 2011, Trends in microbiology.

[19]  H. Radzun,et al.  Chemokine-mediated distribution of dendritic cell subsets in renal cell carcinoma , 2010, BMC Cancer.

[20]  S. Dow,et al.  Type I interferons inhibit the generation of tumor-associated macrophages , 2010, Cancer Immunology, Immunotherapy.

[21]  T. Giese,et al.  Tumour‐derived prostaglandin E2 and transforming growth factor‐β synergize to inhibit plasmacytoid dendritic cell‐derived interferon‐α , 2009, Immunology.

[22]  R. Dina,et al.  Immunopathology and Infectious Diseases Correlation of CXCL 12 Expression and FoxP 3 Cell Infiltration with Human Papillomavirus Infection and Clinicopathological Progression of Cervical Cancer , 2010 .

[23]  Chunhua Lu,et al.  Clinical value of serum HMGB1 levels in early detection of recurrent squamous cell carcinoma of uterine cervix: comparison with serum SCCA, CYFRA21-1, and CEA levels. , 2009, Croatian medical journal.

[24]  Hoguen Kim,et al.  Non-histone nuclear factor HMGB1 is phosphorylated and secreted in colon cancers , 2009, Laboratory Investigation.

[25]  Yi Luo,et al.  Suppression of Dendritic Cells by HMGB1 Is Associated with Lymph Node Metastasis of Human Colon Cancer , 2009, Pathobiology.

[26]  P. Delvenne,et al.  Epithelial metaplasia: adult stem cell reprogramming and (pre)neoplastic transformation mediated by inflammation? , 2009, Trends in molecular medicine.

[27]  P. Delvenne,et al.  High expression of PGE2 enzymatic pathways in cervical (pre)neoplastic lesions and functional consequences for antigen-presenting cells , 2009, Cancer Immunology, Immunotherapy.

[28]  E. Butcher,et al.  Potential role of chemerin in recruitment of plasmacytoid dendritic cells to diseased skin. , 2009, Biochemical and biophysical research communications.

[29]  P. Delvenne,et al.  Transforming growth factor-beta1-mediated Slug and Snail transcription factor up-regulation reduces the density of Langerhans cells in epithelial metaplasia by affecting E-cadherin expression. , 2008, The American journal of pathology.

[30]  I. Mellman,et al.  Plasmacytoid dendritic cells sense self-DNA coupled with antimicrobial peptide , 2007, Nature.

[31]  F. Belardelli,et al.  Interferon-α and cancer : Mechanisms of action and new perspectives of clinical use , 2007 .

[32]  P. Delvenne,et al.  MIP3 alpha stimulates the migration of Langerhans cells in models of human papillomavirus (HPV)-associated (pre)neoplastic epithelium , 2007, Cancer Immunology, Immunotherapy.

[33]  A. Scarpa,et al.  Cooperative Induction of a Tolerogenic Dendritic Cell Phenotype by Cytokines Secreted by Pancreatic Carcinoma Cells1 , 2006, The Journal of Immunology.

[34]  X. Shao,et al.  Influence of IFN- alpha and IFN- gamma on lymphangiogenesis. , 2006, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.

[35]  R. Schreiber,et al.  A critical function for type I interferons in cancer immunoediting , 2005, Nature Immunology.

[36]  Peter P. Nawroth,et al.  Release of High Mobility Group Box 1 by Dendritic Cells Controls T Cell Activation via the Receptor for Advanced Glycation End Products1 , 2005, The Journal of Immunology.

[37]  P. Lenz,et al.  Papillomavirus virus‐like particles induce cytokines characteristic of innate immune responses in plasmacytoid dendritic cells , 2005, European journal of immunology.

[38]  A. Mantovani,et al.  Role of ChemR23 in directing the migration of myeloid and plasmacytoid dendritic cells to lymphoid organs and inflamed skin , 2005, The Journal of experimental medicine.

[39]  G. Trinchieri,et al.  Plasmacytoid dendritic cells in immunity , 2004, Nature Immunology.

[40]  J. Blay,et al.  Dendritic Cell Infiltration and Prognosis of Early Stage Breast Cancer , 2004, Clinical Cancer Research.

[41]  P. Carmeliet,et al.  Dendritic Cell Subsets Differentially Regulate Angiogenesis in Human Ovarian Cancer , 2004, Cancer Research.

[42]  T. Giese,et al.  Identification and functional analysis of tumor-infiltrating plasmacytoid dendritic cells in head and neck cancer. , 2003, Cancer research.

[43]  S. Liang,et al.  IFNα regulates NK cell cytotoxicity through STAT1 pathway , 2003 .

[44]  M. Colonna,et al.  Recruitment of immature plasmacytoid dendritic cells (plasmacytoid monocytes) and myeloid dendritic cells in primary cutaneous melanomas , 2003, The Journal of pathology.

[45]  P. Delvenne,et al.  Detection of Bone Sialoprotein in Human (Pre)neoplastic Lesions of the Uterine Cervix , 2003, Calcified Tissue International.

[46]  B. Wiedenmann,et al.  Effects of interferon alpha on vascular endothelial growth factor gene transcription and tumor angiogenesis. , 2003, Journal of the National Cancer Institute.

[47]  M. Bianchi,et al.  The nuclear protein HMGB1 is secreted by monocytes via a non‐classical, vesicle‐mediated secretory pathway , 2002, EMBO reports.

[48]  T. Misteli,et al.  Release of chromatin protein HMGB1 by necrotic cells triggers inflammation , 2002, Nature.

[49]  John M. Kirkwood,et al.  Cancer immunotherapy: The interferon-α experience , 2002 .

[50]  T. Curiel,et al.  Stromal-derived factor-1 in human tumors recruits and alters the function of plasmacytoid precursor dendritic cells , 2001, Nature Medicine.

[51]  M. Chiasson,et al.  Incidence of cervical squamous intraepithelial lesions in HIV-infected women. , 2000, JAMA.

[52]  A. Mantovani,et al.  Cloning and Characterization of a Specific Receptor for the Novel CC Chemokine MIP-3α from Lung Dendritic Cells , 1997, The Journal of experimental medicine.

[53]  J. Blay,et al.  Impaired IFNa Production by Plasmacytoid Dendritic Cells Favors Regulatory T-cell Expansion That May Contribute to Breast Cancer Progression , 2012 .

[54]  Herbert J Zeh,et al.  High-mobility group box 1 and cancer. , 2010, Biochimica et biophysica acta.

[55]  F. Belardelli,et al.  Interferon-alpha and cancer: mechanisms of action and new perspectives of clinical use. , 2007, Biochimie.

[56]  K. Tracey,et al.  High Mobility Group B1 Protein Suppresses the Human Plasmacytoid Dendritic Cell Response to TLR9 Agonists , 2006 .

[57]  S. Liang,et al.  IFNalpha regulates NK cell cytotoxicity through STAT1 pathway. , 2003, Cytokine.

[58]  John Kirkwood,et al.  Cancer immunotherapy: the interferon-alpha experience. , 2002, Seminars in oncology.